TATA MEMORIAL CENTRE
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1941-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.tmc.gov.in
Clinical Trials
408
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (275 trials with phase data)• Click on a phase to view related trials
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
- Conditions
- Biliary Tract CancerHER2-positive CancerAdvanced CancerUnresectable Biliary Tract CarcinomaMetastatic Biliary Tract Carcinoma
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Tata Memorial Centre
- Target Recruit Count
- 220
- Registration Number
- NCT07062263
- Locations
- 🇮🇳
Homi Bhabha Cancer Hospital and Research Centre, Muzaffarpur, Muzaffarpur, Bihar, India
🇮🇳Tata Memorial Hospital, Mumbai, Maharashtra, India
🇮🇳Institute of Medical Sciences & SUM Hospital, Bhubaneswar, Odisha, India
Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Tata Memorial Centre
- Target Recruit Count
- 18
- Registration Number
- NCT07021677
- Locations
- 🇮🇳
Dr.Sumeet Mirgh, Navi Mumbai, Maharashtra, India
Delphi Process to Achieve Global Consensus on Gender Equity in Critical Care
- Conditions
- Professional RoleResearch Peer Review
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Tata Memorial Centre
- Target Recruit Count
- 45
- Registration Number
- NCT06847802
Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors
- Conditions
- Primary Brain TumorsDiffuse GliomaMeningiomaPituitary AdenomaLow Grade CNS Tumors
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Tata Memorial Centre
- Target Recruit Count
- 156
- Registration Number
- NCT06831461
- Locations
- 🇮🇳
Tata Memorial Centre, Mumbai, India
Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial
- Conditions
- Prostate Carcinoma
- Interventions
- Drug: ADT for 9 months and ARTA for 6 monthsDrug: ADT for 2 years
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Tata Memorial Centre
- Target Recruit Count
- 206
- Registration Number
- NCT06818682
- Locations
- 🇮🇳
Tata Memorial Centre, Mumbai, Maharashtra, India
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
Tata Memorial Centre Partners with GE HealthCare to Establish Advanced Cancer Research & Innovation Centre
Tata Memorial Centre has signed a Memorandum of Understanding with GE HealthCare Technologies Inc. to establish a Cancer Research & Innovation Centre, with TMC serving as the clinical oncology partner and GE HealthCare as the technology partner.
BART Trial: Adjuvant Radiotherapy Shows Tolerable Toxicity Profile in Bladder Cancer
The BART trial investigated adjuvant radiotherapy (ART) following radical cystectomy and chemotherapy in high-risk muscle-invasive bladder cancer (MIBC).
India Launches World's Most Affordable CAR-T Cell Therapy at One-Tenth International Cost
President Droupadi Murmu launched India's first indigenously-developed CAR-T cell therapy, NexCAR19, marking a major breakthrough in the country's battle against cancer.